Ezivac%252525252525252520enema

# Ezivac Enema ## Overview Ezivac enema is a proprietary brand formulation containing **Sodium Phosphate** (monobasic sodium phosphate and dibasic sodium phosphate). It functions as a saline osmotic laxative, drawing water into the colon to induce peristalsis and facilitate evacuation. ## Primary Indications * Relief of occasional constipation. * Bowel preparation prior to proctoscopic or sigmoidoscopic examinations. ## Adult Dosing * **Standard dose:** 1 unit (118–133 mL) administered rectally as a single dose. * **Maximum:** Do not exceed 1 dose in a 24-hour period unless directed by a physician. ## Pediatric Dosing * **Ages ≥12 years:** Same as adult dosing (1 unit). * **Ages 2–11 years:** Usually 1/2 the adult dose (approximately 59–66 mL) or follow specific pediatric unit formulations if available. * **Ages <2 years:** **Contraindicated** due to the high risk of severe electrolyte disturbances. ## Dose Adjustments * **Renal Impairment:** Use with extreme caution. Significant risk of hyperphosphatemia, hypocalcemia, hypernatremia, and acidosis. Avoid in patients with clinically suspected or confirmed renal insufficiency. * **Hydration:** Ensure adequate oral fluid intake before and after administration to minimize dehydration. ## Contraindications * Hypersensitivity to sodium phosphates. * Megacolon (congenital or acquired). * Gastrointestinal obstruction, perforation, or active inflammatory bowel disease. * Congestive heart failure or severe edema (due to sodium load). * Known renal failure. ## Adverse Effects * **Common:** Rectal irritation, abdominal cramping, nausea. * **Serious:** Severe electrolyte imbalances (hyperphosphatemia, hypocalcemia, hypernatremia, hypokalemia), metabolic acidosis, acute phosphate nephropathy, and cardiac arrhythmias secondary to electrolyte shifts. ## Key Drug Interactions * **Diuretics (Loop/Thiazide):** May increase risk of electrolyte imbalance and dehydration. * **ACE Inhibitors/ARBs/NSAIDs:** Concurrent use increases the risk of acute kidney injury or nephrotoxicity. * **Calcium Channel Blockers:** Potential for enhanced hypocalcemic effects. ## Monitoring * Monitor for signs of electrolyte disturbance (paresthesia, confusion, cardiac arrhythmias). * Monitor hydration status. * Assess stool output post-administration. * In institutional settings, baseline and post-procedure serum electrolytes may be indicated for high-risk patients. ## Clinical Pearls * **Safety:** Always lubricate the applicator tip thoroughly to prevent rectal trauma. * **Administration:** Position the patient on the left side with knees bent (Sims' position) to facilitate anatomical flow. * **Efficacy:** If no evacuation occurs within 15–30 minutes, discontinue use and consult a physician; repeated dosing carries a high risk of systemic toxicity. * **Precautions:** Be aware that "Ezivac" branding may vary by region; verify the active ingredients (sodium phosphate vs. bisacodyl or oil-based) before administration. *** *Disclaimer: This information is for educational purposes and does not replace professional medical judgment. Always verify current prescribing information, institutional protocols, and patient-specific contraindications before administering any medication.*